Voxelotor: alteration of sickle cell disease pathophysiology by a first-in-class polymerization inhibitor
Open Access
- 1 January 2021
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Hematology
- Vol. 12
Abstract
Sickle cell disease, despite its recognition as a severely debilitating genetic condition affecting hundreds of thousands of neonates throughout the world each year, was not a target of pharmaceutical research focus for most of its 100-year existence in the medical consciousness. This has changed in recent years as many novel therapeutics are currently under investigation, with three new disease-modifying drugs achieving FDA approval in the last 4 years. One of these drugs, voxelotor, is especially encouraging as an inhibitor of sickling for its ability to safely improve the chronic hemolytic anemia of sickle cell disease. This was demonstrated during all clinical phases of investigation by an average improvement in hemoglobin of greater than 1 g/dL, as well as statistically significant improvements in established markers of hemolysis. While anemia itself represents a potential cause of morbidity, it is more importantly a marker of the hemolysis known to cause the long-term vascular and organ damage that makes sickle cell disease so debilitating and frequently fatal early in life. Given the recency of the approval, there has not been sufficient long-term follow-up to demonstrate improvement in the chronic sequelae of sickle cell disease as a result of voxelotor-induced improvements in hemolytic anemia. There is hope, however, based on the experience with hydroxyurea improving morbidity and mortality via reductions in sickling and improved rheology, that voxelotor may have similar long-term benefits by positively manipulating the kinetics of hemoglobin polymerization. This review aims to summarize the targeted pathobiology of sickle cell disease, the mechanism of action of voxelotor, and the safety and efficacy data from preclinical to late clinical stage investigations of this long-awaited medication, in the hopes of better informing the decision-making process behind prescribing or not prescribing it for patients in need of intervention.Keywords
This publication has 74 references indexed in Scilit:
- The relationship between the severity of hemolysis, clinical manifestations and risk of death in 415 patients with sickle cell anemia in the US and EuropeHaematologica, 2012
- Markers of Severe Vaso-Occlusive Painful Episode Frequency in Children and Adolescents with Sickle Cell AnemiaThe Journal of Pediatrics, 2012
- Crystallographic analysis of human hemoglobin elucidates the structural basis of the potent and dual antisickling activity of pyridyl derivatives of vanillinActa Crystallographica Section D Structural Biology, 2011
- Fetal hemoglobin in sickle cell anemiaBlood, 2011
- Emerging Biobehavioral Factors of Fatigue in Sickle Cell DiseaseJournal of Nursing Scholarship, 2011
- Health‐related quality of life in children with sickle cell disease: A report from the Comprehensive Sickle Cell Centers Clinical Trial ConsortiumPediatric Blood & Cancer, 2010
- Vasculopathy in sickle cell disease: Biology, pathophysiology, genetics, translational medicine, and new research directionsAmerican Journal of Hematology, 2009
- Deconstructing sickle cell disease: Reappraisal of the role of hemolysis in the development of clinical subphenotypesBlood Reviews, 2007
- High risk of recurrent stroke after discontinuance of five to twelve years of transfusion therapy in patients with sickle cell diseaseThe Journal of Pediatrics, 1991
- Erythrocyte Adherence to Endothelium in Sickle-Cell AnemiaNew England Journal of Medicine, 1980